Ovarian cancer laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
==Laboratory finding== | ==Laboratory finding== | ||
* Patients with ovarian cancer can present acutely or sub-acutely | * Patients with ovarian cancer can present acutely or sub-acutely | ||
| Line 16: | Line 14: | ||
**CBC | **CBC | ||
**CBP | **CBP | ||
*Serum biomarkers of epithelial ovarian cancer (EOC): | *Serum biomarkers of epithelial ovarian cancer (EOC):<ref name="pmid11369781">{{cite journal| author=Yin BW, Lloyd KO| title=Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | journal=J Biol Chem | year= 2001 | volume= 276 | issue= 29 | pages= 27371-5 | pmid=11369781 | doi=10.1074/jbc.M103554200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11369781 }} </ref> | ||
** CA 125 | ** CA 125 | ||
*** Considered the best for ovarian cancer detection, therapeutic monitoring, and detection of the tumor recurrence | *** Considered the best for ovarian cancer detection, therapeutic monitoring, and detection of the tumor recurrence | ||
***Postmenopausal woman: should be measured | ***Postmenopausal woman: should be measured | ||
*** Premenopausal woman: should be measured only if US shows highly suspicious malignant mass | *** Premenopausal woman: should be measured only if US shows highly suspicious malignant mass | ||
** HE4 | ** HE4 <ref name="pmid15781627">{{cite journal| author=Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR et al.| title=Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. | journal=Cancer Res | year= 2005 | volume= 65 | issue= 6 | pages= 2162-9 | pmid=15781627 | doi=10.1158/0008-5472.CAN-04-3924 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15781627 }} </ref> | ||
***CA125 and HE4 are used together to increase the sensitivity and specificity of ovarian cancer detection | ***CA125 and HE4 are used together to increase the sensitivity and specificity of ovarian cancer detection | ||
***Risk of Ovarian Malignancy Algorithm (ROMA) is used to decide if the patient has a high risk or low-risk malignant disease based on: | ***Risk of Ovarian Malignancy Algorithm (ROMA) is used to decide if the patient has a high risk or low-risk malignant disease based on: | ||
**** CA125 and HE4 levels | **** CA125 and HE4 levels | ||
**** Menopausal status of the woman | **** Menopausal status of the woman | ||
** OVA1 | ** OVA1<ref name="pmid6310399">{{cite journal| author=Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H et al.| title=A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. | journal=N Engl J Med | year= 1983 | volume= 309 | issue= 15 | pages= 883-7 | pmid=6310399 | doi=10.1056/NEJM198310133091503 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6310399 }} </ref><ref name="pmid2651469">{{cite journal| author=Jacobs I, Bast RC| title=The CA 125 tumour-associated antigen: a review of the literature. | journal=Hum Reprod | year= 1989 | volume= 4 | issue= 1 | pages= 1-12 | pmid=2651469 | doi=10.1093/oxfordjournals.humrep.a136832 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2651469 }} </ref><ref name="pmid15313933">{{cite journal| author=Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al.| title=Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. | journal=Cancer Res | year= 2004 | volume= 64 | issue= 16 | pages= 5882-90 | pmid=15313933 | doi=10.1158/0008-5472.CAN-04-0746 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15313933 }} </ref> | ||
*** | *** | ||
*Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer: | *Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer: | ||
| Line 38: | Line 36: | ||
**DHEA: dehydroepiandrostenedione | **DHEA: dehydroepiandrostenedione | ||
**AMH: anti-Müllerian hormone | **AMH: anti-Müllerian hormone | ||
*The gene for CA 125 was cloned in 2001 and is called MUC16<ref name="pmid11369781">{{cite journal| author=Yin BW, Lloyd KO| title=Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | journal=J Biol Chem | year= 2001 | volume= 276 | issue= 29 | pages= 27371-5 | pmid=11369781 | doi=10.1074/jbc.M103554200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11369781 }} </ref> | |||
*radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer<ref name="pmid6310399">{{cite journal| author=Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H et al.| title=A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. | journal=N Engl J Med | year= 1983 | volume= 309 | issue= 15 | pages= 883-7 | pmid=6310399 | doi=10.1056/NEJM198310133091503 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6310399 }} </ref> | |||
*CA125 and the second generation test (CA125 II) are both cliniclaly equivalent<ref name="pmidPMID 16690492">{{cite journal| author=Mongia SK, Rawlins ML, Owen WE, Roberts WL| title=Performance characteristics of seven automated CA 125 assays. | journal=Am J Clin Pathol | year= 2006 | volume= 125 | issue= 6 | pages= 921-7 | pmid=PMID 16690492 | doi=10.1309/NBA3-12W0-LANR-XYH9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16690492 }} </ref> | |||
Revision as of 16:16, 15 July 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer laboratory findings On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer laboratory findings |
|
Risk calculators and risk factors for Ovarian cancer laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.
Overview
Laboratory finding
- Patients with ovarian cancer can present acutely or sub-acutely
- If there is clinical suspicion of malignancy, the evaluation includes laboratory work, imaging and surgical exploration for the definite diagnosis
- Routine lab work
- CBC
- CBP
- Serum biomarkers of epithelial ovarian cancer (EOC):[1]
- CA 125
- Considered the best for ovarian cancer detection, therapeutic monitoring, and detection of the tumor recurrence
- Postmenopausal woman: should be measured
- Premenopausal woman: should be measured only if US shows highly suspicious malignant mass
- HE4 [2]
- CA125 and HE4 are used together to increase the sensitivity and specificity of ovarian cancer detection
- Risk of Ovarian Malignancy Algorithm (ROMA) is used to decide if the patient has a high risk or low-risk malignant disease based on:
- CA125 and HE4 levels
- Menopausal status of the woman
- OVA1[3][4][5]
- CA 125
- Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer:
- AFP: alpha-fetoprotein
- hCG: human chorionic gonadotropin
- LDH: lactate dehydrogenase
- E2: estradiol
- Inhibin
- Testost: testosterone
- Andro: androstenedione
- DHEA: dehydroepiandrostenedione
- AMH: anti-Müllerian hormone
- The gene for CA 125 was cloned in 2001 and is called MUC16[1]
- radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer[3]
- CA125 and the second generation test (CA125 II) are both cliniclaly equivalent[6]
References
- ↑ 1.0 1.1 Yin BW, Lloyd KO (2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". J Biol Chem. 276 (29): 27371–5. doi:10.1074/jbc.M103554200. PMID 11369781.
- ↑ Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR; et al. (2005). "Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas". Cancer Res. 65 (6): 2162–9. doi:10.1158/0008-5472.CAN-04-3924. PMID 15781627.
- ↑ 3.0 3.1 Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H; et al. (1983). "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N Engl J Med. 309 (15): 883–7. doi:10.1056/NEJM198310133091503. PMID 6310399.
- ↑ Jacobs I, Bast RC (1989). "The CA 125 tumour-associated antigen: a review of the literature". Hum Reprod. 4 (1): 1–12. doi:10.1093/oxfordjournals.humrep.a136832. PMID 2651469.
- ↑ Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ; et al. (2004). "Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer". Cancer Res. 64 (16): 5882–90. doi:10.1158/0008-5472.CAN-04-0746. PMID 15313933.
- ↑ Mongia SK, Rawlins ML, Owen WE, Roberts WL (2006). "Performance characteristics of seven automated CA 125 assays". Am J Clin Pathol. 125 (6): 921–7. doi:10.1309/NBA3-12W0-LANR-XYH9. PMID 16690492 PMID 16690492 Check
|pmid=value (help).